Literature DB >> 3796036

Clinical significance of human bone marrow stromal cell colonies in acute leukemias.

J Hirata, M Katsuno, S Kaneko, T Umemura, J Nishimura, S Motomura, H Ibayashi.   

Abstract

Human bone marrow-derived fibroblastoid colony-forming cells (CFU-F) and adipocyte colonies in 36 patients with acute leukemia were studied, and were serially analysed at different clinical stages. At untreated stage, CFU-F number in acute lymphoblastic leukemia (ALL) was lower than that in acute non-lymphoblastic leukemia (ANL). In ANLs, CFU-F number in M1 was lower than that in M2. Adipocyte colonies were frequently developed at regenerating and relapsing stages, but rarely at untreated and remission stages. The adipocyte colony formation did not correlate with any of CFU-F number, marrow cellularity nor number of leukemic cells, but might be associated with hemopoietic regeneration. The favorable prognosis was associated with normal CFU-F number and with adipocyte colony formation at regenerating or bottom stage. As adipocytes in marrow samples were completely removed before cultures, adipocyte colony was probably originated from preadipocytes. Thus, our results suggest that adipocyte precursor cells increase in regenerating marrow and that they are essential in active hemopoiesis.

Entities:  

Mesh:

Year:  1986        PMID: 3796036     DOI: 10.1016/0145-2126(86)90011-1

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  4 in total

1.  Studies on the relationship between leukemic fibroblast colony forming cell and hemopoietic cells.

Authors:  Y Chen; B M Wang; C Y Li; D J Yu
Journal:  J Tongji Med Univ       Date:  1988

2.  Enumeration of the colony-forming units-fibroblast from mouse and human bone marrow in normal and pathological conditions.

Authors:  Sergei A Kuznetsov; Mahesh H Mankani; Paolo Bianco; Pamela G Robey
Journal:  Stem Cell Res       Date:  2008-08-12       Impact factor: 2.020

3.  Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.

Authors:  Shinichiro Kashiwagi; Yuka Asano; Wataru Goto; Koji Takada; Katsuyuki Takahashi; Satoru Noda; Tsutomu Takashima; Naoyoshi Onoda; Shuhei Tomita; Masahiko Ohsawa; Kosei Hirakawa; Masaichi Ohira
Journal:  PLoS One       Date:  2017-02-06       Impact factor: 3.240

4.  Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer.

Authors:  Shinichiro Kashiwagi; Wakaba Fukushima; Yuka Asano; Wataru Goto; Koji Takada; Satoru Noda; Tsutomu Takashima; Naoyoshi Onoda; Masahiko Ohsawa; Kosei Hirakawa; Masaichi Ohira
Journal:  BMC Cancer       Date:  2017-08-31       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.